US OptionsDetailed Quotes
PTCT250516P80000
- 0.00
- 0.000.00%
15min DelayTrading May 13 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest80.00Strike Price0.00Turnover0.00%IV-75.02%PremiumMay 16, 2025Expiry Date34.29Intrinsic Value100Multiplier3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.34Leverage Ratio--Theta--Rho--Eff Leverage--Vega
PTC Therapeutics Stock Discussion
Sign in to post a comment
The S&P 500 snapped its longest winning streak in 20 years on Monday as markets inched lower amid little significant tariff news coupled with caution ahead of the Federal Reserve's rate decision due out Wednesday.
The $S&P 500 Index (.SPX.US)$ shed 36.29 points (0.6%) to close at 5,650.38, halting a run of consecutive positive sessions at nine – the index's longest winning streak since 2004.
The $Nasdaq Composite Index (.IXIC.US)$ likewise ...
The $S&P 500 Index (.SPX.US)$ shed 36.29 points (0.6%) to close at 5,650.38, halting a run of consecutive positive sessions at nine – the index's longest winning streak since 2004.
The $Nasdaq Composite Index (.IXIC.US)$ likewise ...
11
2
4
$PTC Therapeutics (PTCT.US)$
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
12/19/2024 08:00AM ET
- If approved, vatiquinone would be the first and only authorized therapy for children with FA -
- PTC's fourth approval application submitted to FDA in 2024 -
WARREN, N.J., Dec. 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) ...
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
12/19/2024 08:00AM ET
- If approved, vatiquinone would be the first and only authorized therapy for children with FA -
- PTC's fourth approval application submitted to FDA in 2024 -
WARREN, N.J., Dec. 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) ...
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
20
3
3
$PTC Therapeutics (PTCT.US)$ just dud offering 22.87 a share get out 🔻🔻🔻🔻
PTC Therapeutics' low P/S ratio is seen as reasonable due to industry underperformance. However, weak revenue outlook is pressuring shares, making maintaining current prices challenging. Shareholders accept the low P/S, expecting no future revenue surprises.
Recent insider selling at PTC Therapeutics outweighs insider buying, a potential bearish sign. Despite some insider buying, the long-term outlook lacks positivity. Insider ownership suggests alignment with shareholders, but insider selling warrants caution.
1
PTC Therapeutics' ongoing losses may have led to negative market view, causing a contradictory movement in the stock against the company’s revenue growth. The firm's underperformance in the past five years suggests unresolved issues. Currently, the healthcare company has five investment analysis warning signs.
No comment yet
73685167 : .
74377323 : $NVIDIA (NVDA.US)$